Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)‘s stock had its “hold” rating reiterated by research analysts at BMO Capital Markets in a research note issued to investors on Monday, July 31st. They presently have a $16.00 target price on the stock. BMO Capital Markets’ price objective suggests a potential upside of 7.45% from the company’s current price.

A number of other equities research analysts have also recently weighed in on the company. Piper Jaffray Companies set a $20.00 price objective on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, July 29th. BidaskClub lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 28th. Wells Fargo & Company reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Saturday, July 22nd. TheStreet upgraded Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, June 26th. Finally, Zacks Investment Research lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Amphastar Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $19.86.

Amphastar Pharmaceuticals (NASDAQ AMPH) traded down 2.49% during midday trading on Monday, reaching $14.89. 246,952 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $17.25 and its 200-day moving average price is $15.91. The stock has a market cap of $687.84 million, a PE ratio of 193.38 and a beta of 1.65. Amphastar Pharmaceuticals has a one year low of $12.05 and a one year high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 9th. The company reported $0.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The business had revenue of $65.20 million during the quarter, compared to analysts’ expectations of $63.40 million. During the same period in the previous year, the firm posted $0.23 earnings per share. The company’s revenue was down 4.1% on a year-over-year basis. Equities analysts predict that Amphastar Pharmaceuticals will post $0.40 earnings per share for the current year.

Amphastar Pharmaceuticals announced that its Board of Directors has initiated a share buyback program on Wednesday, August 9th that allows the company to buyback $20.00 million in shares. This buyback authorization allows the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

TRADEMARK VIOLATION WARNING: “Amphastar Pharmaceuticals’ (AMPH) “Hold” Rating Reaffirmed at BMO Capital Markets” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://theolympiareport.com/2017/08/12/bmo-capital-markets-reiterates-hold-rating-for-amphastar-pharmaceuticals-inc-amph-updated.html.

In other news, Director Jason B. Shandell sold 11,482 shares of the business’s stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $16.92, for a total value of $194,275.44. Following the completion of the sale, the director now directly owns 241,342 shares of the company’s stock, valued at approximately $4,083,506.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard K. Prins sold 10,000 shares of the business’s stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $17.07, for a total value of $170,700.00. Following the completion of the sale, the director now directly owns 28,844 shares of the company’s stock, valued at $492,367.08. The disclosure for this sale can be found here. Insiders sold a total of 36,482 shares of company stock valued at $620,125 over the last three months. Company insiders own 11.10% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. boosted its position in shares of Amphastar Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after buying an additional 842 shares during the period. SG Americas Securities LLC bought a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at about $111,000. State of Alaska Department of Revenue boosted its position in shares of Amphastar Pharmaceuticals by 77.2% in the second quarter. State of Alaska Department of Revenue now owns 7,052 shares of the company’s stock valued at $125,000 after buying an additional 3,072 shares during the period. Municipal Employees Retirement System of Michigan boosted its position in shares of Amphastar Pharmaceuticals by 3.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 8,200 shares of the company’s stock valued at $119,000 after buying an additional 290 shares during the period. Finally, Mason Street Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 8,394 shares of the company’s stock valued at $122,000 after buying an additional 549 shares during the period. Hedge funds and other institutional investors own 44.02% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.